ITGAM and allergic asthma: A study using a BALB/c mouse model demonstrated that the administration of chemerin attenuated allergic airway inflammation, decreased the accumulation of CD4+ T cells and eosinophils in the bronchoalveolar lavage fluid of mice with allergic asthma, and decreased the gene expression of the Th2-attracting chemokines CCL17 and CCL22, causing suppression of the airway recruitment of inflammatory CD11c+CD11b+ dendritic cells [22].